Tags : Boehringer Ingelheim

Boehringer Ingelheim Reports Results of BI 425809 in P-II Study

Shots: The P-II study involves assessing of BI 425809 (4 oral doses, qd) vs PBO over 12wks. treatment period in schizophrenia patients. The results are presented at the 33rd ECNP Congress Results: met its 1EPs and showed improvement in cognition in stable adult schizophrenia patients. The results are being further evaluated in cognitive impairment associated […]Read More

Boehringer Ingelheim and Click Collaborate on Digital Therapy for Behaviour

Shots: Click to receive $500M as up front, funding for research and development activities, clinical, regulatory & commercial milestones along with royalties on sales of CT-155 globally, will lead research and development activities and support Boehringer Ingelheim in global commercialization activities The companies will join their expertise to develop the mobile application, CT-155, which combines […]Read More

Boehringer Ingelheim and Pharmaxis Halt the Development of BI 1467335

Shots: The companies discontinue the P-IIa study assessing BI 1467335 vs PBO in 79 patients with moderately severe to severe NPDR without CIDME for 12wks. treatment period with an additional 12wks. follow-up period afterward. The study met its 1EPs in ocular safety with the treatment being well-tolerated The discontinuation is due to a lack of […]Read More

Boehringer Ingelheim Collaborates with BiomX to Discover Microbiome-Based Biomarkers for

Shots: BiomX will generate metagenomic data of gut microbiome samples obtained from IBD patients with the focus of identifying biomarkers using the XMarker platform Boehringer Ingelheim gets an option to negotiate an exclusive right to biomarkers discovered under the collaboration. The XMarker platform supports the phage therapy for IBD, BX002, via analysis of real-world metagenomic […]Read More

Boehringer Ingelheim Acquires GST to Boost its Stem Cell Capabilities

Shots: Boehringer Ingelheim has acquired Global Stem cell Technology (GST) focusing to strengthen its portfolio capabilities to accelerate innovation and growth The acquisition follows two years of partnership b/w the companies that brought the first-ever registered stem cell-based veterinary medicine (Arti-Cell Forte) in the EU The acquisition of GST will accelerate the development pipeline of […]Read More

G1 Therapeutics and Boehringer Ingelheim Collaborate to Co-Promote Trilaciclib for

Shots: Boehringer to receive payments to cover start-up expenses and pre-approval initiatives for a successful commercial launch. Additionally, it receives mid-twenties percentage of net sales in the 1st yr. of commercialization, which decreases to a low double-digit/high single-digit percentage in the 2nd and 3rd year respectively G1 will book revenue in the selective territories and […]Read More

Boehringer Ingelheim Receives Approval for its Classical Swine Fever Live

Shots: Boehringer’s Ingelvac CSF MLV has obtained a New Veterinary Drug Registration Certificate from the Ministry of Agriculture and Rural Affairs of China The vaccine is jointly developed by Boehringer and Chinese research institutes and will be produced at BI’s Taizhou plant, Jiangsu province, and is expected to be commercialized in H1’21 The vaccine is […]Read More

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline to

Shots: Shots: Boehringer Ingelheim acquires two preclinical programs from Northern Biologic to foster its cancer immunology portfolio in exchange Northern will receive upfront, milestones and other consideration payments. The acquisition will support Boehringer’s strategy to target ‘’cold tumors with synergistic combination approaches” The first program is an Ab inhibitor of Periostin, which contributes to cancer […]Read More